US approves Eli Lilly's GLP-1 pill Foundayo: A new front in expanding weight-loss medication market

The US Food and Drug Administration has approved a once-daily oral GLP-1 pill from Eli Lilly, setting the stage for a high-stakes rivalry with Novo Nordisk in the next phase of the blockbuster weight-loss drug market.

The drug, generically known as orforglipron and to be sold under the brand name Foundayo, will be available in the United States starting April 6. It marks a significant shift in a market that has so far been dominated by injectable GLP-1 therapies such as Novo Nordisk’s Wegovy.

A pill to widen access

Unlike existing injectable treatments, Foundayo is a once-daily oral medication targeting the GLP-1 hormone, which regulates appetite and blood sugar. In clinical trials, patients lost between 12 per cent and 15 per cent of their body weight — placing it firmly among the most effective obesity drugs currently available.

What differentiates Foundayo is not just its format but also its chemistry. Unlike Novo Nordisk’s peptide-based oral GLP-1 pill, Lilly’s drug is a small-molecule compound, structurally closer to widely used medications such as statins or blood-pressure drugs. This could make it easier and cheaper to manufacture at scale, while also offering a more familiar regimen for patients accustomed to daily pills.

More from Business

April visa shake-up: New rules to hit Indians travelling to US, UK, Canada, Europe Top 5 Indian CEOs leading multibillion dollar US firms

The convenience factor could prove decisive. Foundayo can be taken at any time of day, with or without food — a contrast to Novo’s oral Wegovy, which must be taken under stricter conditions, including fasting requirements.

Market expansion beyond injectables

Analysts say the arrival of effective oral GLP-1 drugs could significantly broaden the addressable market. While injectable therapies have seen explosive demand, a large segment of patients remains reluctant to adopt injections.

Early data suggests oral drugs are already bringing in first-time users. Industry estimates indicate pills could account for roughly 20 per cent of the GLP-1 market by the end of the decade, expanding the sector beyond its current base.

Lilly’s chief executive has indicated the company is targeting both weight-loss and weight-maintenance segments, with regulatory filings already underway in more than 40 countries.

Renewed Lilly–Novo rivalry

The approval intensifies competition between Lilly and Novo Nordisk, which have dominated the GLP-1 segment for diabetes and obesity. Novo was the first to market with injectable drugs like Ozempic and Wegovy, and also gained an early lead in oral formulations.

However, Lilly has recently taken the lead in the US injectable market, and Foundayo positions it to challenge Novo’s early-mover advantage in pills.

Quick Reads

View All

Iran war: IEA, IMF and World Bank join hands to tackle history’s worst supply disruption

India renews essential commodity exports to Maldives for 2026–27 under 1981 pact

The competitive stakes are high. The GLP-1 market has transformed both companies into some of the world’s most valuable pharmaceutical firms, while also triggering ripple effects across industries — from food and beverages to health insurance and bariatric surgery.

Pricing, safety and rollout

Lilly said Foundayo will initially be priced at $149 per month for the lowest dose for self-paying patients, broadly in line with competing oral treatments. The drug will first be distributed through LillyDirect before expanding to retail pharmacies and telehealth platforms.

Like other GLP-1 drugs, Foundayo carries a boxed warning — the FDA’s most serious safety label — regarding a potential risk of thyroid tumours. The most common side effects reported in trials were gastrointestinal, including nausea and vomiting.

The drug was approved under a fast-track pathway tied to a US government voucher programme aimed at accelerating access to treatments deemed to have public health importance.

A structural shift in healthcare

The approval underscores a broader transition in how obesity is treated — from lifestyle interventions and surgery to long-term pharmacological management.

With oral GLP-1 drugs now entering the mainstream, the next phase of competition is likely to focus not just on efficacy, but on convenience, pricing, and global accessibility.

For patients — and for a healthcare system grappling with rising obesity rates — the shift from injections to pills could prove to be a pivotal turning point.